Literature DB >> 25056507

Enhancing population pharmacokinetic modeling efficiency and quality using an integrated workflow.

Henning Schmidt1, Andrijana Radivojevic.   

Abstract

Population pharmacokinetic (popPK) analyses are at the core of Pharmacometrics and need to be performed regularly. Although these analyses are relatively standard, a large variability can be observed in both the time (efficiency) and the way they are performed (quality). Main reasons for this variability include the level of experience of a modeler, personal preferences and tools. This paper aims to examine how the process of popPK model building can be supported in order to increase its efficiency and quality. The presented approach to the conduct of popPK analyses is centered around three key components: (1) identification of most common and important popPK model features, (2) required information content and formatting of the data for modeling, and (3) methodology, workflow and workflow supporting tools. This approach has been used in several popPK modeling projects and a documented example is provided in the supplementary material. Efficiency of model building is improved by avoiding repetitive coding and other labor-intensive tasks and by putting the emphasis on a fit-for-purpose model. Quality is improved by ensuring that the workflow and tools are in alignment with a popPK modeling guidance which is established within an organization. The main conclusion of this paper is that workflow based approaches to popPK modeling are feasible and have significant potential to ameliorate its various aspects. However, the implementation of such an approach in a pharmacometric organization requires openness towards innovation and change-the key ingredient for evolution of integrative and quantitative drug development in the pharmaceutical industry.

Entities:  

Mesh:

Year:  2014        PMID: 25056507     DOI: 10.1007/s10928-014-9370-4

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  11 in total

Review 1.  Population pharmacokinetics I: background, concepts, and models.

Authors:  Ene I Ette; Paul J Williams
Journal:  Ann Pharmacother       Date:  2004-08-24       Impact factor: 3.154

2.  Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success.

Authors:  Klaus Romero; Brian Corrigan; Christoffer W Tornoe; Jogarao V Gobburu; Meindert Danhof; William R Gillespie; Marc R Gastonguay; Bernd Meibohm; Hartmut Derendorf
Journal:  J Clin Pharmacol       Date:  2010-09       Impact factor: 3.126

3.  Pharmacometrics 2020.

Authors:  Jogarao V S Gobburu
Journal:  J Clin Pharmacol       Date:  2010-09       Impact factor: 3.126

Review 4.  Population pharmacokinetics. A regulatory perspective.

Authors:  H Sun; E O Fadiran; C D Jones; L Lesko; S M Huang; K Higgins; C Hu; S Machado; S Maldonado; R Williams; M Hossain; E I Ette
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 5.  The use of population pharmacokinetics in drug development.

Authors:  S Vozeh; J L Steimer; M Rowland; P Morselli; F Mentre; L P Balant; L Aarons
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 6.  Fundamentals of Population Pharmacokinetic Modelling : Modelling and Software.

Authors:  Tony K L Kiang; Catherine M T Sherwin; Michael G Spigarelli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2012-08       Impact factor: 6.447

7.  Facilitating pharmacometric workflow with the metrumrg package for R.

Authors:  Timothy T Bergsma; William Knebel; Jeannine Fisher; William R Gillespie; Matthew M Riggs; Leonid Gibiansky; Marc R Gastonguay
Journal:  Comput Methods Programs Biomed       Date:  2012-09-29       Impact factor: 5.428

Review 8.  Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses: an industry perspective.

Authors:  P L Bonate; A Strougo; A Desai; M Roy; A Yassen; J S van der Walt; A Kaibara; S Tannenbaum
Journal:  AAPS J       Date:  2012-07-24       Impact factor: 4.009

Review 9.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

10.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17
View more
  3 in total

1.  QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models.

Authors:  Yougan Cheng; Craig J Thalhauser; Shepard Smithline; Jyotsna Pagidala; Marko Miladinov; Heather E Vezina; Manish Gupta; Tarek A Leil; Brian J Schmidt
Journal:  AAPS J       Date:  2017-05-24       Impact factor: 4.009

2.  Steady-state volume of distribution of two-compartment models with simultaneous linear and saturated elimination.

Authors:  Xiaotian Wu; Fahima Nekka; Jun Li
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-07-12       Impact factor: 2.745

3.  Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages.

Authors:  Matthew Fidler; Justin J Wilkins; Richard Hooijmaijers; Teun M Post; Rik Schoemaker; Mirjam N Trame; Yuan Xiong; Wenping Wang
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-07-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.